Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Visual benefits with faricimab given at up to 16-week intervals demonstrates its potential
to meaningfully extend the time between treatments with sustained efficacy, thereby
reducing treatment burden in patients with nAMD.